N-[2-[[5-(5-aminopyridin-2-yl)-1-[4-(difluoromethylidene)piperidin-1-yl]-1-oxopentan-2-yl]sulfamoyl]-6-phenylphenyl]acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-[[5-(5-aminopyridin-2-yl)-1-[4-(difluoromethylidene)piperidin-1-yl]-1-oxopentan-2-yl]sulfamoyl]-6-phenylphenyl]acetamide
• 化学式: C₃₀H₃₃F₂N₅O₄S
• 分子量: 597.7
• InChiKey: CZDGBCPZABMRBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  42
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  143
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• SUBSTITUTED OXAZOLIDINONES AND USE THEREOF
  申请人：Rohrig Susanne

  公开号：US20100184767A1

  公开（公告）日：2010-07-22

  The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.

  该发明涉及新型取代氧唑烷酮，其制备方法，其用于治疗和/或预防疾病以及用于制备用于治疗和/或预防疾病，特别是血栓栓塞性疾病的药物的用途。
• SUBSTITUTED OXAZOLIDINONES AND THEIR USE
  申请人：Bayer Intellectual Property GmbH

  公开号：US20140057951A1

  公开（公告）日：2014-02-27

  The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.

  本发明涉及新型取代的噁唑烷酮，以及它们的制备方法，它们的用途用于治疗和/或预防疾病以及它们用于制备治疗和/或预防疾病的药物，特别是血栓栓塞性疾病。
• SUBSTITUIERTE (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHEN-CARBOXAMIDE UND IHRE VERWENDUNG IM GEBIET DER BLUTGERINNUNG
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2173744B1

  公开（公告）日：2011-10-05
• SUBSTITUIERTE OXAZOLIDINONE UND IHRE VERWENDUNG
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2167499B1

  公开（公告）日：2011-12-14
• Oxazolidinones For the Treatment and/or Prophylaxis of Heart Failure
  申请人：Kallabis Harald

  公开号：US20110003804A1

  公开（公告）日：2011-01-06

  The present invention relates to the use of selective inhibitors of coagulation factor Xa, in particular of oxazolidinones of the formula (I), for the treatment and/or prophylaxis of heart failure and/or disorders related to heart failure as well as their use for the preparation of pharmaceutical drugs for the treatment and/or prophylaxis of heart failure and/or disorders related to heart failure.